With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapies for cancer. Our clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of transfusion-dependent β-thalassemia (also known as β-thalassemia major); a single-center Phase 1/2 study in France (HGB-205) for the treatment of transfusion-dependent β-thalassemia or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of severe sickle cell disease (HGB-206). Our first immuno-oncology application will use CAR T cell technology to target B cell maturation antigen (BCMA) in multiple myeloma, and we anticipate treating the first patient in our Phase 1 study in the first quarter of 2016. We also have ongoing preclinical immuno-oncology programs targeting hematological and solid tumors, as well as discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies.

If you've previously created a job alert prior to June 9th, 2015, please take a moment to create one on our new site. We'd hate for you to miss out on a great new opportunity at bluebird.

Enter Search Terms
Filter Your Results

This is an exciting time to join the field of gene therapy in general, and to become a part of the bluebird bio team in particular. bluebird bio is a publicly traded company on the NASDAQ Global Select Market and trades under the symbol BLUE. We offer a fast-paced, dynamic, collaborative, colorful, and scientifically rigorous environment, with all the fun and passion that a start-up provides, plus an excellent benefits package that includes stock options, commuter/parking benefit, etc.

If you've previously created a job alert prior to June 9th, 2015, please take a moment to create one on our new site. We'd hate for you to miss out on a great new opportunity at bluebird.